1. Meeting the Global Challenge 2014.06.03 ~ 06.07 International workshop on antiviral drug resistance

2. Workshop Objectives Characterize resistance to new antiviral agents Assess mechanisms and pathogenesis of antiviral resistanc e Identify the clinical implications of antiviral resistance Discuss new developments in epidemiology of antiviral resi stance Review new technologies and analyses of antiviral resistan ce Target Audience: This workshop was designed to interest p hysicians, clinicians, scientists and clinical researchers in th e antiviral resistance area

3. Programme Session 1 : Epidemiology of antiviral resistance Session 2: New resistance technologies and interp retations Session 3: Antiviral drug resistance in resource-limi ted countries Session 4: Antiviral drug resistance Session 5: Clinical implications of antiviral resistan ce Session 6: Mechanisms and pathogenesis of antivi ral resistance

4. Epidemiology of resistance The purpose of HIV drug resistance surveillance HIV drug resistance surveillance: what are the implications for program mes in low and middle-income countries?  Strategy shift Detect an alert  Quantify the magnitude of HIV DR Results area/clinic specific  Results are nationally representative Focus on clinic functioning  Focus on ART programme functioning

5. 2014 revised WHO HIVDR Surveillance Strategy - Routine M&E (clinic level) o Early Warning Indicators; identifies clinic level weaknesses allowing co rrective action - HIVDR survey (national level) o Pre-treatment HIVDR in ART starters; 1 st -line regimen selection (new) o Acquired HIVDR; programme performance in achieving VL suppressio n, proportion VF with wild type, 2 nd & 3 rd line regimen selection o HIVDR in infants <18 months; 1 st -line paediatric regimen selection o Transmitted HIVDR in recently infected populations; programme quality (indirect indicator) (http://www.who.int/hiv/topics/drugresistance/en/)

6. Hepatitis B forum, Next steps in treating patients with chron ic hapatitis B: can we cure this disease? Keynote address: Immune dysfunction in CHB: the role of T-cell lymphocyte exhaustion Viral eradication in the chronically infected woodch uck model of HBC Eradication strategies: can we eliminate or silence cccDNA and cure CHB? HBV eradication strategies: non-cccDNA targets a nd eradication Achieving a cure in hepatitis B

7. Hepatitis C forum, Resistance to direct antiviral drugs in HC V infection: Just academic or of clinical relevance? Pre-existence of HCV variants conferring resistance to DAAs: as sessment, frequencies, and consequences for antiviral therapies ? Resistance to PI-based triple therapies: do we need direct, clonal or deep sequencing and can we retreat patients with PIs? Molecular mechanisms for mode of action and resistance to NS5 A inhibitors Clinical resistance to NS5A inhibitors: virologic escape and long-t erm persistence HCV nucleoside to NS5A polymerase inhibitors: antiviral activitie s and barriers to resistance among different HCV genotype and s ubtypes Importance of resistance to interferon-free regimens: potential pr oblems for re-treatment after failure to initial DAA combinations